ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Tuesday, November 9, 2021

2:15PM-2:30PM: Abstract Number: 1906

IL-13Ra1-Mediated Signaling Regulates Age-Associated/Autoimmune B-Cell Expansion and Lupus Pathogenesis

Abstracts: B Cell Biology & Targets in Autoimmune & Inflammatory Disease (1905–1908)

2:30PM-2:45PM: Abstract Number: 1921

Axial Psoriatic Arthritis: Correlation Between Whole Spine MRI Abnormalities and Clinical Findings

Abstracts: Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes II (1919–1922)

2:30PM-2:45PM: Abstract Number: 1907

Increased Otoferlin Expression in B Cells Is Associated with Muscle Weakness in Untreated Juvenile Dermatomyositis: A Pilot Study

Abstracts: B Cell Biology & Targets in Autoimmune & Inflammatory Disease (1905–1908)

2:30PM-2:45PM: Abstract Number: 1911

Patient’s and Rheumatologist’s Perspectives on the Burden of Adverse Drug Reactions Attributed to Biologics: A Qualitative Study

Abstracts: Patient Outcomes, Preferences, & Attitudes (1909–1914)

2:30PM-2:45PM: Abstract Number: 1917

Sputum TGF-β1 Is Elevated in Subclinical and Clinically Significant Rheumatoid Arthritis-Associated Interstitial Lung Disease and Correlates with Soluble IL-6R Levels

Abstracts: RA – Diagnosis, Manifestations, & Outcomes II: Heart & Lung (1915–1918)

2:45PM-3:00PM: Abstract Number: 1918

Don’t Forget About the Arthritis in RA-ILD! Impact of Pulmonary and RA Disease Severity on Survival

Abstracts: RA – Diagnosis, Manifestations, & Outcomes II: Heart & Lung (1915–1918)

2:45PM-3:00PM: Abstract Number: 1922

Early and Accurate Diagnosis of Patient with Axial Spondyloarthritis Using Machine Learning: A Predictive Analysis from Electronic Health Records in United Kingdom

Abstracts: Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes II (1919–1922)

2:45PM-3:00PM: Abstract Number: 1908

Interferon (IFN)-Stimulated Gene 15: A Novel Biomarker for Lymphoma Development in Sjögren’s Syndrome

Abstracts: B Cell Biology & Targets in Autoimmune & Inflammatory Disease (1905–1908)

2:45PM-3:00PM: Abstract Number: 1912

Meteorological Variables Have Different Effect on Core Measures of Disease Activity in Patients with Rheumatoid Arthritis

Abstracts: Patient Outcomes, Preferences, & Attitudes (1909–1914)

3:00PM-3:15PM: Abstract Number: 1913

Patient Perceptions of Telemedicine Use in Rheumatology Clinics During the COVID-19 Pandemic: An Analysis from the COVID-19 Global Rheumatology Alliance

Abstracts: Patient Outcomes, Preferences, & Attitudes (1909–1914)

3:15PM-3:30PM: Abstract Number: 1914

Immunomodulatory and Immunosuppressive Medication Modification Among Rheumatology Patients at the Time of COVID-19 Vaccination

Abstracts: Patient Outcomes, Preferences, & Attitudes (1909–1914)

3:30PM-3:45PM: Abstract Number: 1923

Has the Incidence of Total Joint Arthroplasty in Rheumatoid Arthritis Decreased in the Era of Biologics Use? A Population-based Incident Cohort Study 1995–2015

Abstracts: Epidemiology & Public Health II: Inflammatory Arthritis (1923–1926)

3:30PM-3:45PM: Abstract Number: 1927

Heterogeneity of Juvenile Idiopathic Arthritis Synovial Fibroblasts Correlates to Disease Progression and Provides Compelling Diagnostic Data

Abstracts: Pediatric Rheumatology – Basic Science (1927–1930)

3:30PM-3:45PM: Abstract Number: 1931

The Burden of Thirty-day Readmission and Independent Predictors of Readmission in Patients with Systemic Lupus Erythematosus: A Nationwide Analysis

Abstracts: SLE – Diagnosis, Manifestations, & Outcomes II: Predictors & Longitudinal Outcomes (1931–1934)

3:45PM-4:00PM: Abstract Number: 1932

Identifying Clusters of Longitudinal Autoantibody Profiles Associated with Systemic Lupus Erythematosus Disease Outcomes

Abstracts: SLE – Diagnosis, Manifestations, & Outcomes II: Predictors & Longitudinal Outcomes (1931–1934)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].